Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.55 |
| ▸ | TUBB | P07437 | 2/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.55 |
| ▸ | AHR | P35869 | 2/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12028758 | 1.00 | KDM4E (0.59) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL15929665 | 0.86 | KDM4E (0.53) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL11608130 | 0.83 | KDM4E (0.55) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL11608132 | 0.83 | KDM4E (0.55) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL7740467 | 0.82 | HIF1A (0.54) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL4881152 | 0.81 | RELA (0.81) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL631998 | 0.81 | RELA (0.81) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL13790336 | 0.81 | RELA (0.81) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL699458 | 0.81 | RELA (0.81) | KDM4ECYP3A4LMNAALDH1A1TP53 | |
| SCHEMBL699457 | 0.81 | RELA (0.81) | KDM4ECYP3A4LMNAALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-9394268-B2 | (E)-1-(5-methoxy-2,2-dimethyl-2H-chromen-8-yl)-3-(4-methoxyphenyl)prop-2-en-1-one and analogs thereof, as well as preparation method and use thereof | SICHUAN UNIVERSITY (CN) | 2016-07-19 | — | — | US | disclosed |
| US-9198420-B2 | Rodenticidal norbormide analogues | LANDCARE RESEARCH NEW ZEALAND LIMITED (NZ) | 2015-12-01 | — | — | US | disclosed |
| US-9101628-B2 | Methods and composition of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-9079869-B2 | Chiral disulfonimides | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9035287-B2 | Polymeric materials for use in metal-oxide-semiconductor field-effect transistors | POLYERA CORPORATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150133659-A1 | (E)-1-(5-METHOXY-2,2-DIMETHYL-2H-CHROMEN-8-YL)-3-(4-METHOXYPHENYL)PROP-2-EN-1-ONE AND ANALOGS THEREOF, AS WELL AS PREPARATION METHOD AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2015-05-14 | — | — | US | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-20150025113-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | ANIMAL CONTROL PRODUCTS LIMITED (NZ) | 2015-01-22 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120009615-A1 | DIPYRROMETHENE-BORON HYDROPHILIC FLUORESCENT COMPOUNDS | UNIVERSITE DE STRASBOURG (50% PART INTEREST) (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20100261722-A1 | HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-14 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025113-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | CASP7, RANBP1, CASP3 | KDM4E 2937/4885CYP3A4 778/4885LMNA 2399/4885 |
| US-20150133659-A1 | (E)-1-(5-METHOXY-2,2-DIMETHYL-2H-CHROMEN-8-YL)-3-(4-METHOXYPHENYL)PROP-2-EN-1-ONE AND ANALOGS THEREOF, AS WELL AS PREPARATION METHOD AND USE THEREOF | ECE1, CMA1, MME | KDM4E 86/4885CYP3A4 193/4885LMNA 424/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | KDM4E 56/4885CYP3A4 24/4885LMNA 4270/4885 |
| US-20100261722-A1 | HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES | NR0B1, NR1H3, CCR10 | KDM4E 1522/4885CYP3A4 131/4885LMNA 2119/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | KDM4E 56/4885CYP3A4 24/4885LMNA 4270/4885 |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | KDM4E 2789/4885CYP3A4 3175/4885LMNA 1863/4885 |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | KDM4E 4710/4885CYP3A4 1116/4885LMNA 2224/4885 |
| US-20120009615-A1 | DIPYRROMETHENE-BORON HYDROPHILIC FLUORESCENT COMPOUNDS | LDHB, AHR, BCR | KDM4E 4804/4885CYP3A4 2316/4885LMNA 94/4885 |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | KDM4E 628/4885CYP3A4 180/4885LMNA 1234/4885 |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STS, SUDS3, SF1 | KDM4E 2415/4885CYP3A4 873/4885LMNA 1831/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | KDM4E 925/4885CYP3A4 2026/4885LMNA 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.